Share on StockTwits

InterMune (NASDAQ:ITMN) EVP Paul D. Arata sold 7,500 shares of InterMune stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $50.00, for a total value of $375,000.00. Following the completion of the sale, the executive vice president now directly owns 21,913 shares of the company’s stock, valued at approximately $1,095,650. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on ITMN shares. Analysts at Goldman Sachs downgraded shares of InterMune from a “buy” rating to a “neutral” rating in a research note on Thursday. They now have a $49.00 price target on the stock, down previously from $52.06. They noted that the move was a valuation call. Separately, analysts at William Blair raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Friday, August 8th. Finally, analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $45.15.

Shares of InterMune (NASDAQ:ITMN) traded down 1.00% during mid-day trading on Thursday, hitting $51.54. 5,161,598 shares of the company’s stock traded hands. InterMune has a one year low of $10.95 and a one year high of $54.57. The stock’s 50-day moving average is $44.09 and its 200-day moving average is $34.36. The company’s market cap is $5.565 billion. InterMune also saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 9,575,169 shares, a drop of 16.4% from the July 15th total of 11,458,044 shares. Based on an average daily volume of 1,796,186 shares, the short-interest ratio is presently 5.3 days. Currently, 9.9% of the shares of the company are sold short.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the previous year, the company posted ($0.77) earnings per share. The company’s revenue for the quarter was up 141.2% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.73 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.